Oncolytics Biotech
Open
$0.90
Prev. Close
$0.90
High
$0.90
Low
$0.90
Market Snapshot
$90.27M
-3.1
-0.30
28
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-05. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
emptyResult
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-05. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Recently from Cashu
Oncolytics Biotech Targets Immuno-Oncology Growth with Innovative Treatments and Promising Trial Results
### Oncolytics Biotech Positions Itself in the Growing Immuno-Oncology Sector Oncolytics Biotech Inc. is making significant strides in the rapidly evolving oncology market, which is projected to exper…
Oncolytics Biotech Launches Promising Trial for Metastatic Colorectal Cancer Treatment Advances
Oncolytics Biotech Advances Treatment Options for Metastatic Colorectal Cancer Oncolytics Biotech Inc. is making strides in the battle against metastatic colorectal cancer, particularly among patients…
Oncolytics Biotech Advances Colorectal Cancer Therapy with Promising Trial Results
Oncolytics Biotech's Innovative Approach to Colorectal Cancer Treatment Oncolytics Biotech Inc. leads the charge in redefining treatment protocols in the oncology sector, particularly with its randomi…
Oncolytics Biotech Focuses on Immuno-Oncology Growth and Regulatory Pathways for Pelareorep
Oncolytics Biotech Targets Critical Growth Areas in Immuno-Oncology Oncolytics Biotech Inc. is strategically aligning itself within the burgeoning immuno-oncology sector, which is poised for significa…